Circulating Tumor DNA Testing for Minimal Residual Disease and Its Application in Colorectal Cancer
Oluseyi Abidoye(Mayo Clinic), Mohamad Bassam Sonbol(WinnMed), Mitesh J. Borad(Jacksonville College), Christina Wu(Mayo Clinic Hospital), Daniel H. Ahn(Mayo Clinic Hospital), Tanios Bekaii‐Saab(WinnMed), Sakti Chakrabarti(Mayo Clinic in Arizona)
Cited by 19
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
|Cell Reports|2017|619
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
|JAMA Oncology|2019|472
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
|The Lancet. Gastroenterology & hepatology|2021|423